Stifel Nicolaus Has Lowered Expectations for Inventiva (NASDAQ:IVA) Stock Price

Posted by Steven Smith on Nov 22nd, 2024

Inventiva (NASDAQ:IVA – Get Free Report) had its price target reduced by research analysts at Stifel Nicolaus from $20.00 to $17.00 in a research report issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock.

A number of other equities research analysts have also issued reports on IVA. UBS Group initiated coverage on shares of Inventiva in a research note on Tuesday, November 12th. They set a “neutral” rating and a $3.00 target price for the company. HC Wainwright dropped their price objective on shares of Inventiva from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, October 15th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.25.

Read Our Latest Analysis on IVA

Inventiva Price Performance

Shares of NASDAQ IVA traded down $0.08 during trading on Friday, hitting $2.66. 14,169 shares of the company were exchanged, compared to its average volume of 76,257. Inventiva has a 1 year low of $1.53 and a 1 year high of $4.75. The firm’s fifty day moving average price is $2.37 and its 200 day moving average price is $2.66.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Inventiva stock. Virtu Financial LLC purchased a new position in shares of Inventiva S.A. (NASDAQ:IVA – Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 10,490 shares of the company’s stock, valued at approximately $38,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

(Get Free Report)

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.